ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PRAX vs JNJ // EV/EBITDA & P/E VALUATION

Praxis Precision Medicines Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: PRAX 2 — JNJ 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRAX VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PRAX JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -3.09% 2.97% -6.06 JNJ /fcf-yield <GO>
Operating Margin — 34.70% — TIE /operating-margins <GO>
Net Profit Margin — 28.50% — TIE /net-margins <GO>
Revenue Growth (YoY) 8.80% 6.00% +2.80 PRAX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 5.59 +20.41 PRAX /balance-sheet <GO>
Piotroski F-Score Quality 5/9 8/9 -3.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.3 62.1 -5.80 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.91 1.08 -0.17 JNJ /macro-sensitivity <GO>
Forward P/E Multiple 33.0x 23.0x +10.00 JNJ /forward-pe <GO>
Enterprise Scale & Market Cap $8.06B $662.49B -$654.43B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PRAX REV JNJ REV PRAX GROSS % JNJ GROSS % PRAX FCF JNJ FCF
FY 2025 $0 $94.19B — 67.9% -$249.1M $19.70B
FY 2024 $8.6M $88.82B — 69.1% -$131.8M $19.84B
FY 2023 $2.4M $85.16B — — -$111.2M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRAX // BETA 0.91
JNJ // BETA 1.08